company background image
SLDB

Solid Biosciences NasdaqGS:SLDB Stock Report

Last Price

US$6.58

Market Cap

US$49.6m

7D

-3.5%

1Y

-74.9%

Updated

29 Nov, 2022

Data

Company Financials +
SLDB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

SLDB Stock Overview

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States.

Solid Biosciences Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Solid Biosciences
Historical stock prices
Current Share PriceUS$6.58
52 Week HighUS$30.75
52 Week LowUS$5.89
Beta1.37
1 Month Change7.69%
3 Month Change-31.46%
1 Year Change-74.93%
3 Year Change-89.87%
5 Year Changen/a
Change since IPO-98.06%

Recent News & Updates

Recent updates

Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

Apr 30
Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

Apr 28
Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Mar 17
We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans

Oct 28
Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Jul 13
We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely

Mar 17
We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely

Shareholder Returns

SLDBUS BiotechsUS Market
7D-3.5%-1.0%-0.9%
1Y-74.9%-15.2%-18.9%

Return vs Industry: SLDB underperformed the US Biotechs industry which returned -16.1% over the past year.

Return vs Market: SLDB underperformed the US Market which returned -20.5% over the past year.

Price Volatility

Is SLDB's price volatile compared to industry and market?
SLDB volatility
SLDB Average Weekly Movement6.9%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: SLDB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: SLDB's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013104Ilan Ganothttps://www.solidbio.com

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company’s lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients’ muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids.

Solid Biosciences Inc. Fundamentals Summary

How do Solid Biosciences's earnings and revenue compare to its market cap?
SLDB fundamental statistics
Market CapUS$49.58m
Earnings (TTM)-US$89.44m
Revenue (TTM)US$11.25m

4.4x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SLDB income statement (TTM)
RevenueUS$11.25m
Cost of RevenueUS$12.99m
Gross Profit-US$1.74m
Other ExpensesUS$87.70m
Earnings-US$89.44m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-11.87
Gross Margin-15.45%
Net Profit Margin-795.16%
Debt/Equity Ratio0%

How did SLDB perform over the long term?

See historical performance and comparison